Colorectal Cancer | Specialty

Neoadjuvant, Nonoperative Regimens Being Investigated in Rectal Cancer

April 10th 2018

Katherine Van Loon, MD, MPH, discusses the emerging use of neoadjuvant therapy and nonoperative approaches for patients with locally advanced rectal cancer.

Dr. Bekaii-Saab Discusses the Next Steps With Regorafenib in CRC

April 3rd 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the next steps following for regorafenib (Stivarga) in colorectal cancer (CRC).

Precision Medicine Impact Grows in GI Cancer Paradigm

March 30th 2018

Bert H. O’Neil, MD, discusses the role of molecular testing throughout GI cancers and highlights the current and developing treatment landscape for patients with colorectal cancer.

Expert Sheds Light on Recent Advances in mCRC

March 29th 2018

Shubham Pant, MD, shares his insight on the future direction of the treatment landscape of colorectal cancer.

Dr. O'Neil Discusses the Current Treatment of Patients With CRC

March 28th 2018

Bert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses the current treatment of patients with colorectal cancer.

Dr. Pant on the Future of mCRC Treatment

March 28th 2018

Shubham Pant, MD, associate medical director of the Clinical & Translational Research Center, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses ongoing efforts in metastatic colorectal cancer (mCRC) and his hope for the future treatment landscape.

FDA Grants Nivolumab/Ipilimumab Priority Review for MSI-H/dMMR Colorectal Cancer

March 27th 2018

The FDA has granted a priority review to a supplemental biologics license application for nivolumab plus ipilimumab for the treatment of adult patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer following progression on a fluoropyrimidine, oxaliplatin, and irinotecan.

Immunotherapy, Sidedness Strategies Enhancing mCRC Treatment

March 23rd 2018

Chloe E. Atreya, MD, PhD, discusses the latest treatment advances in mCRC, including tumor sidedness and emerging immunotherapy strategies.

Dr. Van Loon on the PROSPECT Trial

March 21st 2018

Katherine Van Loon, MD, gastrointestinal cancer specialist, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the design of the multicenter PROSPECT trial.

Dr. Overman on the Impact of Nivolumab in mCRC

March 21st 2018

Michael J. Overman, MD, associate professor, department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the impact of nivolumab (Opdivo) on the treatment of patients with metastatic colorectal cancer (mCRC).

Atezolizumab, Cobimetinib Combo Active in mCRC

March 19th 2018

Atezolizumab in combination with cobimetinib induced a 31% disease control rate in patients with heavily-pretreated metastatic colorectal cancer.

Venook Highlights Impact of IDEA Trial in Colon Cancer

March 19th 2018

Alan P. Venook, MD, discusses the significance of the findings of the international IDEA study investigating doses of FOLFOX for patients with colon cancer.

NCCN Recommends Regorafenib Dose Escalation in Metastatic CRC

March 16th 2018

The NCCN has updated its colorectal cancer (CRC) guidelines, recommending a weekly regorafenib dose-escalation strategy beginning at 80 mg and ending at 160 mg for previously treated patients with metastatic CRC.

Dr. Atreya on How the NCCN Guidelines Have Impacted Treatment Options in mCRC

March 14th 2018

Chloe E. Atreya, MD, PhD, assistant clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the molecular subgroups in metastatic colorectal cancer (mCRC) and viable treatment options for patients with microsatellite instability (MSI)-high and BRAF-mutated cancers.

Dr. Venook Discusses Adjuvant Chemotherapy Duration in CRC

March 7th 2018

Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses adjuvant chemotherapy duration in colon cancer.

Nut Consumption Linked to Survival Benefit in Colon Cancer

March 3rd 2018

Patients with stage III colon cancer who ate at least 2 servings of nuts per week had superior disease-free survival and overall survival.

Nut consumption may aid colon cancer survival

March 1st 2018

People with stage III colon cancer who regularly eat nuts are at significantly lower risk of cancer recurrence and mortality than those who don

First Liver Transplant Surgery Performed in Patient With CRC Metastases

February 28th 2018

Although the standard-of-care treatment for patients with liver metastases developing from colorectal cancer is liver resection, only one-third of these patients are candidates for surgery.

Dr. Morse Reflects on Recent Data in Advanced CRC

February 27th 2018

Michael A. Morse, MD, professor, Medicine, Department of Surgery, Duke University School of Medicine, Duke Cancer Institute, reflects on recent data in advanced colorectal cancer.

Improving Outcomes in CRC

February 26th 2018